{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:14:56Z","timestamp":1788052496682,"version":"build-2784847793"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005283","name":"Foundation for Scientific and Technological Development and Support of Cear\u00e1","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005283","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordination for the improvement of Higher Education Personnel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119186","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:53:26Z","timestamp":1785772406000},"page":"119186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Epigenetic strategies for fetal hemoglobin induction in sickle cell disease"],"prefix":"10.1016","volume":"318","author":[{"given":"Mateus Mello","family":"de Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline Renata","family":"Pavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Gabriel","family":"de Faria Pastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Lu\u00edsa","family":"Rodriguez Gini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronaldo","family":"de Ara\u00fajo Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Lanaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulcin\u00e9ia Martins","family":"de Albuquerque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Ferreira","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cau\u00ea Benito","family":"Scarim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Hodgkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Leandro","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119186_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejmech.2026.119186_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010\u20132050: modelling based on demographics, excess mortality, and interventions","volume":"10","author":"Piel","year":"2013","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejmech.2026.119186_bib3","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(23)00118-7","article-title":"Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000\u20132021: a systematic analysis from the global Burden of Disease Study 2021","volume":"10","author":"Thomson","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ejmech.2026.119186_bib4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","article-title":"Pathophysiology of sickle cell disease","volume":"14","author":"Sundd","year":"2019","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ejmech.2026.119186_bib5","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/nm1202-799","article-title":"Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease","volume":"8","author":"Reiter","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.119186_bib6","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1172\/JCI89741","article-title":"Intravascular hemolysis and the pathophysiology of sickle cell disease","volume":"127","author":"Kato","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.119186_bib7","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1182\/blood.2021014894","article-title":"HbS promotes TLR4-mediated monocyte activation and proinflammatory cytokine production in sickle cell disease","volume":"140","author":"Allali","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119186_bib8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13430","article-title":"The vaso\u2010occlusive pain crisis in sickle cell disease: definition, pathophysiology, and management","volume":"105","author":"Darbari","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ejmech.2026.119186_bib9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/ejh.13212","article-title":"Insight into the complex pathophysiology of sickle cell anaemia and possible treatment","volume":"102","author":"Piccin","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ejmech.2026.119186_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD012187.pub2","article-title":"Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults","author":"Cooper","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2026.119186_bib11","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3389\/fimmu.2020.00454","article-title":"The red blood cell\u2014inflammation vicious circle in sickle cell disease","volume":"11","author":"Nader","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119186_bib12","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood.2022018078","article-title":"Sickle cell inflammation: is HbS the answer?","volume":"140","author":"Gibb","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119186_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2019.154933","article-title":"Pro-inflammatory cytokines associate with NETosis during sickle cell vaso-occlusive crises","volume":"127","author":"Barbu","year":"2020","journal-title":"Cytokine"},{"key":"10.1016\/j.ejmech.2026.119186_bib14","series-title":"FDA is Alerting Patients and Health Care Professionals About the Voluntary Withdrawal of Oxbryta from the Market due to Safety Concerns","year":"2026"},{"key":"10.1016\/j.ejmech.2026.119186_bib16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1172\/JCI200316672","article-title":"Hydroxyurea induces fetal hemoglobin by the nitric oxide\u2013dependent activation of soluble guanylyl cyclase","volume":"111","author":"Cokic","year":"2003","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.119186_bib17","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2007-05-088732","article-title":"Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells","volume":"111","author":"Cokic","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119186_bib18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1535370219900637","article-title":"L-glutamine for sickle cell disease: Knight or pawn?","volume":"245","author":"Sadaf","year":"2020","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.ejmech.2026.119186_bib19","first-page":"2008","article-title":"Advances in sickle cell disease treatments, Cur","volume":"28","author":"Pavan","year":"2021","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119186_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1002063","article-title":"Perspectives and challenges to discovering hemoglobin-inducing agents in Sickle Cell Disease","volume":"9","author":"Pavan","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.ejmech.2026.119186_bib21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1749-6632.2010.05574.x","article-title":"Transcriptional silencing of fetal hemoglobin by BCL11A","volume":"1202","author":"Sankaran","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119186_bib22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.trsl.2014.05.002","article-title":"Epigenetic regulation of fetal globin gene expression in adult erythroid cells","volume":"165","author":"Ginder","year":"2015","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejmech.2026.119186_bib23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nm.3101","article-title":"Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction","volume":"19","author":"Shi","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.119186_bib24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bcmd.2015.10.004","article-title":"Therapeutic fetal-globin inducers reduce transcriptional repression in hemoglobinopathy erythroid progenitors through distinct mechanisms","volume":"56","author":"Dai","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ejmech.2026.119186_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/nyas.13012","article-title":"Chromatin looping as a target for altering erythroid gene expression","volume":"1368","author":"Krivega","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119186_bib26","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2003-05-1738","article-title":"Effects of 5-aza-2\u2032-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease","volume":"102","author":"Saunthararajah","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119186_bib27","doi-asserted-by":"crossref","first-page":"9790","DOI":"10.3390\/ijms23179790","article-title":"Histone deacetylases function in the control of early hematopoiesis and erythropoiesis","volume":"23","author":"Vong","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119186_bib28","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1182\/blood.2018892737","article-title":"Inhibition of LSD1 by small molecule inhibitors stimulates fetal hemoglobin synthesis","volume":"133","author":"Le","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119186_bib29","article-title":"Identification of small molecule agonists of fetal hemoglobin expression for the treatment of sickle cell disease","volume":"19","author":"Yang","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119186_bib30","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1182\/blood.2023022190","article-title":"Elevating fetal hemoglobin: recently discovered regulators and mechanisms","volume":"144","author":"Khandros","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119186_bib31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bbmt.2015.10.017","article-title":"Indications and results of HLA-identical sibling hematopoietic cell transplantation for sickle cell disease","volume":"22","author":"Walters","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ejmech.2026.119186_bib32","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119186_bib33","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-Thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119186_bib34","series-title":"FDA, Lyfgenia (Lovotibeglogene Autotemcel): Highlights of Prescribing Information, bluebird Bio","year":"2023"},{"key":"10.1016\/j.ejmech.2026.119186_bib35","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1089\/crispr.2024.0042","article-title":"Affordable pricing of CRISPR treatments is a pressing ethical imperative","volume":"7","author":"Rueda","year":"2024","journal-title":"CRISPR J."},{"key":"10.1016\/j.ejmech.2026.119186_bib36","first-page":"1694","article-title":"Casgevy and Lyfgenia: two gene therapies for sickle cell disease","author":"Medical Letter","year":"2024","journal-title":"Med. Lett. Drugs Ther."},{"key":"10.1016\/j.ejmech.2026.119186_bib37","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1182\/blood-2010-11-316893","article-title":"Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities","volume":"117","author":"Wilber","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119186_bib38","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/genes14030577","article-title":"Epigenetic regulation of \u03b2-Globin genes and the potential to treat hemoglobinopathies through epigenome editing","volume":"14","author":"Fontana","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.ejmech.2026.119186_bib39","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood-2005-05-2113","article-title":"Regulation of human fetal hemoglobin: new players, new complexities","volume":"107","author":"Bank","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119186_bib40","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/emboj.2011.450","article-title":"Dynamic long\u2010range chromatin interactions control Myb proto\u2010oncogene transcription during erythroid development","volume":"31","author":"Stadhouders","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2026.119186_bib41","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/ng1244","article-title":"The \u03b2-globin nuclear compartment in development and erythroid differentiation","volume":"35","author":"Palstra","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2026.119186_bib42","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1172\/JCI71520","article-title":"HBS1L-MYB intergenic variants modulate fetal hemoglobin via long-range MYB enhancers","volume":"124","author":"Stadhouders","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.119186_bib43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.molcel.2004.12.028","article-title":"Proximity among distant regulatory elements at the \u03b2-Globin locus requires GATA-1 and FOG-1","volume":"17","author":"Vakoc","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.119186_bib44","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.aad3312","article-title":"Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin","volume":"351","author":"Masuda","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119186_bib45","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bcmd.2010.05.006","article-title":"Binding patterns of BCL11A in the globin and GATA1 loci and characterization of the BCL11A fetal hemoglobin locus","volume":"45","author":"Jawaid","year":"2010","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ejmech.2026.119186_bib46","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41573-018-0003-2","article-title":"Therapeutic strategies for sickle cell disease: towards a multi-agent approach","volume":"18","author":"Telen","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119186_bib47","doi-asserted-by":"crossref","first-page":"12617","DOI":"10.1073\/pnas.1006774107","article-title":"Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease","volume":"107","author":"Bradner","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.119186_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0323550","article-title":"The histone deacetylase inhibitor CT-101 flips the switch to fetal hemoglobin expression in sickle cell disease mice","volume":"20","author":"Takezaki","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119186_bib49","first-page":"229","article-title":"Fetal hemoglobin induction by the histone deacetylase inhibitor, scriptaid","volume":"51","author":"Johnson","year":"2005","journal-title":"Cell. Mol. Biol. (Noisy-Le-Grand)"},{"key":"10.1016\/j.ejmech.2026.119186_bib50","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1126\/science.1165409","article-title":"Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A","volume":"322","author":"Sankaran","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119186_bib51","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1101\/gad.1897310","article-title":"Transcriptional silencing of \u03b3-globin by BCL11A involves long-range interactions and cooperation with SOX6","volume":"24","author":"Xu","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2026.119186_bib52","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/s41588-019-0453-4","article-title":"Rational targeting of a NuRD subcomplex guided by comprehensive in situ mutagenesis","volume":"51","author":"Sher","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2026.119186_bib53","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1021\/jm0303094","article-title":"Histone deacetylase inhibitors","volume":"46","author":"Miller","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119186_bib54","first-page":"1790","article-title":"Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease","volume":"93","author":"Atweh","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119186_bib55","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1182\/blood-2003-02-0478","article-title":"Induction of human \u03b3 globin gene expression by histone deacetylase inhibitors","volume":"103","author":"Cao","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119186_bib56","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/blood-2002-02-0353","article-title":"Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo","volume":"100","author":"Pace","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119186_bib57","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ajh.23306","article-title":"A phase 1\/2 trial of HQK\u20101001, an oral fetal globin inducer, in sickle cell disease","volume":"87","author":"Kutlar","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejmech.2026.119186_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.23533","article-title":"A dose\u2010escalation phase IIa study of 2,2\u2010dimethylbutyrate (HQK\u20101001), an oral fetal globin inducer, in sickle cell disease","volume":"88","author":"Kutlar","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejmech.2026.119186_bib59","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ajh.23725","article-title":"A double\u2010blind, placebo\u2010controlled phase II study of the efficacy and safety of 2,2\u2010dimethylbutyrate (HQK\u20101001), an oral fetal globin inducer, in sickle cell disease","volume":"89","author":"Reid","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejmech.2026.119186_bib60","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.exphem.2015.04.005","article-title":"RN-1, a potent and selective lysine-specific demethylase 1 inhibitor, increases \u03b3-globin expression, F-reticulocytes, and F-cells in a sickle cell disease mouse model","volume":"43","author":"Rivers","year":"2015","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ejmech.2026.119186_bib61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0301-472X(02)01030-5","article-title":"Hydroxamide derivatives of short-chain fatty acids are potent inducers of human fetal globin gene expression","volume":"31","author":"Skarpidi","year":"2003","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ejmech.2026.119186_bib62","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1182\/blood.V120.21.3259.3259","article-title":"Induction of human fetal hemoglobin expression by selective inhibitors of histone deacetylase 1 and 2 (HDAC1\/2)","volume":"120","author":"Shearstone","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119186_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153767","article-title":"Chemical inhibition of histone deacetylases 1 and 2 induces fetal hemoglobin through activation of GATA2","volume":"11","author":"Shearstone","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119186_bib64","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood.V126.23.3378.3378","article-title":"The histone deacetylase 1 and 2 (HDAC1\/2) inhibitor ACY-957 increases epsilon (HbE) and gamma (HbG) Globin mRNA in the peripheral blood of non-anemic rats and monkeys","volume":"126","author":"Shearstone","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119186_bib65","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.V128.22.323.323","article-title":"The histone deacetylase 1 and 2 (HDAC1\/2) inhibitor ACY-957: impact of dosing schedule on pharmacokinetics (PK), pharmacodynamics (PD), hematopoietic toxicity, and gamma Globin (HBG, \u0263) expression in monkey","volume":"128","author":"Chonkar","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119186_bib66","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.119186_bib67","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1080\/17460441.2022.2141708","article-title":"The state of the art of fetal hemoglobin-inducing agents","volume":"17","author":"Pavan","year":"2022","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119186_bib68","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1182\/blood.V114.22.2568.2568","article-title":"LBH589 (panobinostat): a potential novel anti-switching therapy","volume":"114","author":"Kutlar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119186_bib69","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/bjh.12814","article-title":"Modulation of gamma globin genes expression by histone deacetylase inhibitors: an in vitro study","volume":"165","author":"Ronzoni","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2026.119186_bib70","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0955-0674(00)00208-8","article-title":"Histone methylation versus histone acetylation: new insights into epigenetic regulation","volume":"13","author":"Rice","year":"2001","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119186_bib71","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1101\/gad.927301","article-title":"Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails","volume":"15","author":"Zhang","year":"2001","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2026.119186_bib72","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","article-title":"Histone demethylation mediated by the nuclear amine oxidase homolog LSD1","volume":"119","author":"Shi","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119186_bib73","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature04020","article-title":"LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription","volume":"437","author":"Metzger","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119186_bib74","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/s12276-020-00542-2","article-title":"LSD1: more than demethylation of histone lysine residues","volume":"52","author":"Perillo","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119186_bib75","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s10020-026-01421-8","article-title":"Enhanced induction of fetal hemoglobin by the combination of decitabine with RN-1 in \u03b2-thalassemia\/HbE erythroid progenitor cells","volume":"32","author":"Nualkaew","year":"2026","journal-title":"Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119186_bib76","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a011643","article-title":"The switch from fetal to adult hemoglobin","volume":"3","author":"Sankaran","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejmech.2026.119186_bib77","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1021\/acs.jmedchem.0c02176","article-title":"Reversible lysine specific demethylase 1 (LSD1) inhibitors: a promising wrench to impair LSD1","volume":"64","author":"Dai","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119186_bib78","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3390\/molecules29020550","article-title":"Lysine-specific demethylase 1 inhibitors: a comprehensive review utilizing computer-aided drug design technologies","volume":"29","author":"Han","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119186_bib79","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-019-0811-9","article-title":"LSD1\/KDM1A inhibitors in clinical trials: advances and prospects","volume":"12","author":"Fang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119186_bib80","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/med.21334","article-title":"Reversible inhibitors of LSD1 as therapeutic agents in Acute Myeloid leukemia: clinical significance and progress to date","volume":"35","author":"Mould","year":"2015","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.119186_bib81","article-title":"A state-of-the-art review on LSD1 and its inhibitors in breast cancer: molecular mechanisms and therapeutic significance","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119186_bib82","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1021\/bi0618621","article-title":"trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1","volume":"46","author":"Schmidt","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2026.119186_bib83","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1021\/cn200104y","article-title":"Brain-Penetrant LSD1 inhibitors can block memory consolidation","volume":"3","author":"Neelamegam","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2026.119186_bib84","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood-2015-02-626259","article-title":"The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice","volume":"126","author":"Cui","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119186_bib85","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3324\/haematol.2015.140749","article-title":"The LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis)","volume":"101","author":"Rivers","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2026.119186_bib86","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2016-10-746727","article-title":"Efficacy and safety of long-term RN-1 treatment to increase HbF in baboons","volume":"129","author":"Ibanez","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119186_bib87","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0289860","article-title":"Effect of the LSD1 inhibitor RN-1 on \u03b3-globin and global gene expression during erythroid differentiation in baboons (Papio anubis)","volume":"18","author":"Ibanez","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119186_bib88","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.exphem.2018.08.003","article-title":"Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons","volume":"67","author":"Rivers","year":"2018","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ejmech.2026.119186_bib89","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1016\/j.celrep.2018.03.012","article-title":"Enhancer activation by pharmacologic displacement of LSD1 from GFI1 induces differentiation in Acute Myeloid leukemia","volume":"22","author":"Maiques-Diaz","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.119186_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1120911","article-title":"LSD1 inhibitors for cancer treatment: focus on multi-target agents and compounds in clinical trials","volume":"14","author":"Noce","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119186_bib91","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood.2024028006","article-title":"Novel, potent, and orally bioavailable LSD1 inhibitors induce fetal hemoglobin synthesis in a sickle cell disease mouse model","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119186_bib92","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1053\/j.seminhematol.2018.04.008","article-title":"Fetal hemoglobin induction by epigenetic drugs","volume":"55","author":"Lavelle","year":"2018","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.ejmech.2026.119186_bib93","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2174\/15680096113139990077","article-title":"DNA Methyltransferase-1 inhibitors as epigenetic therapy for cancer","volume":"13","author":"Singh","year":"2013","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ejmech.2026.119186_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107328","article-title":"Non-nucleoside inhibitors of DNMT1 and DNMT3 for targeted cancer therapy","volume":"207","author":"Chen","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.119186_bib95","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002382","article-title":"Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: a randomized phase 1 study","volume":"14","author":"Molokie","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejmech.2026.119186_bib96","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.3324\/haematol.2020.248658","article-title":"In vitro and in vivo induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor","volume":"106","author":"Gilmartin","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2026.119186_bib97","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202513469","article-title":"Discovery of a novel DNMT1 inhibitor with improved efficacy in treating \u03b2\u2010thalassemia","volume":"13","author":"Shen","year":"2026","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejmech.2026.119186_bib98","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.3324\/haematol.2021.278791","article-title":"BET inhibitors enhance embryonic and fetal globin expression in erythroleukemia cell lines","volume":"106","author":"Cao","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2026.119186_bib99","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.3324\/haematol.2018.210963","article-title":"Disruption of the MBD2-NuRD complex but not MBD3-NuRD induces high level HbF expression in human adult erythroid cells","volume":"104","author":"Yu","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2026.119186_bib100","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.3324\/haematol.2019.230904","article-title":"A new target for fetal hemoglobin reactivation","volume":"104","author":"Rivers","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2026.119186_bib101","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1021\/jm0603015","article-title":"The physicochemical challenges of designing multiple ligands","volume":"49","author":"Morphy","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119186_bib102","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2174\/138161209787315594","article-title":"Designing multiple ligands \u2013 medicinal chemistry strategies and challenges","volume":"15","author":"Morphy","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2026.119186_bib103","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.2174\/1568026619666190619115735","article-title":"Molecular hybridization as a tool for designing multitarget drug candidates for complex diseases","volume":"19","author":"Ivasiv","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119186_bib104","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.3390\/molecules26092601","article-title":"Hybrid Drugs\u2014A strategy for overcoming anticancer drug resistance?","volume":"26","author":"Szumilak","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119186_bib105","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/17460441.2024.2322990","article-title":"Molecular hybridization: a powerful tool for multitarget drug discovery","volume":"19","author":"de Sena Murteira Pinheiro","year":"2024","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119186_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115938","article-title":"Dual inhibitors of HDAC and other epigenetic regulators: a novel strategy for cancer treatment","volume":"263","author":"Shirbhate","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119186_bib107","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1016\/j.celrep.2020.01.091","article-title":"Mechanism of crosstalk between the LSD1 demethylase and HDAC1 deacetylase in the CoREST complex","volume":"30","author":"Song","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.119186_bib108","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1177\/15353702211028195","article-title":"Exploring epigenetic and microRNA approaches for \u03b3-globin gene regulation","volume":"246","author":"Starlard-Davenport","year":"2021","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.ejmech.2026.119186_bib109","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252211886","article-title":"Genetic modifiers of hemoglobin expression from a clinical perspective in hemoglobinopathy patients with beta thalassemia and sickle cell disease","volume":"25","author":"Diamantidis","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119186_bib110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41467-017-02242-4","article-title":"Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors","volume":"9","author":"Kalin","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119186_bib111","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ejmech.2017.09.038","article-title":"Design and synthesis of tranylcypromine derivatives as novel LSD1\/HDACs dual inhibitors for cancer treatment","volume":"140","author":"Duan","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119186_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108847","article-title":"The LSD1\/HDAC dual-target inhibitor for cancer therapy: challenge and opportunity","volume":"164","author":"Shen","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119186_bib113","doi-asserted-by":"crossref","first-page":"16480","DOI":"10.1021\/acs.jmedchem.4c01310","article-title":"Development of a first-in-class DNMT1\/HDAC inhibitor with improved therapeutic potential and potentiated antitumor immunity","volume":"67","author":"Chang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119186_bib114","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2302254120","article-title":"MBD2a\u2013NuRD binds to the methylated \u03b3-globin gene promoter and uniquely forms a complex required for silencing of HbF expression","volume":"120","author":"Shang","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.119186_bib115","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.chembiol.2021.04.011","article-title":"Targeted protein degradation: a promise for undruggable proteins","volume":"28","author":"Samarasinghe","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119186_bib116","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1002\/cmdc.202000574","article-title":"Targeted protein degradation as a promising tool for epigenetic upregulation of fetal hemoglobin","volume":"15","author":"Verheul","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.119186_bib117","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1039\/D0CC01485K","article-title":"PROTAC-Mediated degradation of class I histone deacetylase enzymes in corepressor complexes","volume":"56","author":"Smalley","year":"2020","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2026.119186_bib118","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1021\/acs.jmedchem.1c02179","article-title":"Optimization of class I histone deacetylase PROTACs reveals that HDAC1\/2 degradation is critical to induce apoptosis and cell arrest in cancer cells","volume":"65","author":"Smalley","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119186_bib119","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4155\/fmc-2021-0206","article-title":"Designing HDAC-PROTACs: lessons learned So far","volume":"14","author":"Fischer","year":"2022","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119186_bib120","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2425812122","article-title":"Discovery of an LSD1 PROTAC degrader","volume":"122","author":"Hosseini","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.119186_bib121","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41588-021-00817-y","article-title":"Targeting ZNF410 as a potential \u03b2-hemoglobinopathy therapy","volume":"53","author":"Tumburu","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2026.119186_bib122","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41588-021-00843-w","article-title":"ZNF410 represses fetal globin by singular control of CHD4","volume":"53","author":"Vinjamur","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2026.119186_bib123","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.molcel.2020.11.006","article-title":"ZNF410 uniquely activates the NuRD component CHD4 to silence fetal hemoglobin expression","volume":"81","author":"Lan","year":"2021","journal-title":"Mol. Cell"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:18:41Z","timestamp":1788049121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":122,"alternative-id":["S0223523426006318"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119186","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic strategies for fetal hemoglobin induction in sickle cell disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119186"}}